Infant Bacterial Therapeutics AB (publ) (STO:IBT.B)

Sweden · Delayed Price · Currency is SEK

75.00

+3.80 (5.34%)

Oct 13, 2026, 5:07 PM CET

Infant Bacterial Therapeutics AB Earnings Call Transcripts

Fiscal Year 2024

Study Update
A large study in premature infants showed no statistical significance for primary endpoints (NEC and feeding tolerance), but demonstrated a significant 27% reduction in all-cause mortality with a strong safety profile. Regulatory submission is planned, leveraging the robust mortality benefit and existing precedents for approval based on secondary endpoints.

Read full transcript →

Press release